Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | CASP3 | P42574 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18359346 | 1.00 | MDM4 (0.59) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29398498 | 1.00 | MDM4 (0.59) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29367434 | 1.00 | MDM4 (0.59) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL119455 | 1.00 | MDM4 (0.59) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29440768 | 1.00 | MDM4 (0.59) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL1228254 | 1.00 | MDM4 (0.59) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29349650 | 1.00 | MDM4 (0.59) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL30291593 | 1.00 | MDM4 (0.59) | MDM4TP53CASP3KMT2AMDM2 | |
| Ammonia Solution, Strong SCHEMBL27827995 | 0.99 | MDM4 (0.58) | MDM4TP53CASP3KMT2AMDM2 | |
| Fluoride SCHEMBL7153172 | 0.99 | MDM4 (0.58) | MDM4TP53CASP3KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332299-A1 | COMPOUND TARGETING SSTR2, PREPARATION METHOD THEREFOR AND USE THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO LTD (CN) | 2025-10-30 | — | — | US | claimed |
| EP-4613758-A1 | COMPOUNDS TARGETING SSTR2, PREPARATION METHOD THEREFOR, AND USE THEREOF | Yantai Lannacheng Biotechnology Co., Ltd. (CN) | 2025-09-10 | — | — | EP | claimed |
| WO-2024120415-A1 | COMPOUNDS TARGETING SSTR2, PREPARATION METHOD THEREFOR, AND USE THEREOF | 烟台蓝纳成生物技术有限公司 | 2024-06-13 | — | — | WO | claimed |
| CN-110357947-B | Combretastatin A4 derivative | 南京恒远科技开发有限公司 | 2023-05-26 | — | — | CN | claimed |
| CN-115583989-B | SSTR 2-targeted compound and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-02-28 | — | — | CN | claimed |
| CN-115583989-A | SSTR 2-targeted compound and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-01-10 | — | — | CN | claimed |
| CN-113045774-B | Double-network composite hydrogel or hydrogel ball containing nano-silver and preparation method and application thereof | 江汉大学 | 2022-05-13 | — | — | CN | claimed |
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| CN-109701013-B | Targeted nano drug delivery system and preparation method thereof | 安徽工程大学 | 2021-07-13 | — | — | CN | claimed |
| CN-113045774-A | Double-network composite hydrogel or hydrogel ball containing nano-silver and preparation method and application thereof | 江汉大学 | 2021-06-29 | — | — | CN | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-110669110-A | Preparation process of RGD cyclized pentapeptide | 南京恒远科技开发有限公司 | 2020-01-10 | — | — | CN | claimed |
| CN-109701013-A | A kind of targeted nanometer drug delivery system and preparation method | 安徽工程大学 | 2019-05-03 | — | — | CN | claimed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-4714499-A2 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2026-03-25 | — | — | EP | disclosed |
| US-5371076-A | ANTIBIOTICS | AMERICAN CYANAMID COMPANY (US) | 1994-12-06 | — | — | US | disclosed |
| EP-0618190-A1 | 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1994-10-05 | — | — | EP | disclosed |
| WO-1994021673-A1 | ALPHA-KETOAMIDE DERIVATIVES AS INHIBITORS OF THROMBOSIS | CORVAS INTERNATIONAL, INC. (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | MDM4 3741/4885TP53 1141/4885CASP3 1489/4885 |
| US-20250332299-A1 | COMPOUND TARGETING SSTR2, PREPARATION METHOD THEREFOR AND USE THEREOF | SSTR2, SSTR5, SSTR3 | MDM4 4630/4885TP53 2881/4885CASP3 3801/4885 |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | CETP, SLC43A1, SLC27A1 | MDM4 884/4885TP53 403/4885CASP3 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.